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Exosomes are gaining importance because they show great promise in therapeutic 
applications for several diseases. Particularly in stroke, exosomes derived from mesenchymal 
stem cell (MSC) therapy work as paracrine effectors responsible for promoting neurovascular 
remodeling and functional recovery. Adult male rats were subjected to intracerebral 
hemorrhage (ICH) by intrastriatal injection of collagenase type IV; 24 h after surgery, MSC-
derived exosomes were administered through the tail vein. The rats were euthanized at 7 or 
28 days after treatment. Functional evaluation, lesion size, fiber tract integrity, axonal 
sprouting and white matter repair markers, biodistribution of exosomes and secretome 
proteomics were analyzed. DiI-labeled exosomes were found in the brains of the ICH-treated 
group and in the liver, lung and spleen. Animals receiving treatment with exosomes showed 
significantly better results in terms of functional recovery, lesion size, fiber tract integrity, 
axonal sprouting and white matter repair markers compared with the control group 28 days 
after stroke. Proteomics analysis of the exosomes identified more than 2000 proteins that 
could be implicated in brain repair function. In conclusion, white matter integrity was partly 
restored by exosome administration mediated by molecular repair factors. Exosomes as a 
treatment could be a heterogeneous process by nature and presents many factors that can 
influence brain plasticity in an adaptable and versatile manner. 
 
Introduction 
After decades of research focused on the search for a treatment for cortical strokes in 
experimental models in which the gray matter is most affected, a few translational studies are 
beginning to highlight the importance of considering the white matter component after 
damage.1,2 The high frequency of this damage motivates the search for an effective therapy to 
enhance the mechanisms underlying the repair of damaged white matter (axons and myelin) 
after a stroke. 
Stem cell therapy is emerging as a viable repair therapy for the treatment of hemorrhagic 
stroke not only with gray matter affection, but including white matter injury.3–5 One of the 
most striking findings is that stem cells are not integrated into residing neural networks but 
act indirectly, promoting brain repair and functional recovery.6 Although the mechanisms by 
which stem cell therapy act are still unknown, recent evidence has suggested they might be 
related to long-distance cell-tocell communication by paracrine function through secretory 
factors in the extracellular environment.7 
Extracellular vesicles, including exosomes, microvesicles and apoptotic bodies have become 
recognized as important in cellular communication (particularly in paracrine and endocrine 
signaling8) and might be responsible for the long-distance effects of stem cell therapy. 
Specifically, exosomes derived from stem cells have recently been suggested to mediate 
restorative stem cell effects.9 Exosomes carry a concentrated group of functional molecules 
(DNA, ribosomal RNA, circular RNA, long noncoding RNA, microRNA, proteins and lipids) 
that serve as intercellular communicators not only locally but also systemically. These 
molecules are involved in many biological processes,8,10 and are an interesting source of 
therapeutic applications in the field of regenerative medicine for neural disabilities including 
another type of stroke: cerebral infarct.7,11 In particular, extracellular vesicles induce long-
term brain protection, promote gray matter repair and neurological recovery and they 
modulate the peripheral post-stroke immune response.7 
All these observations suggest the importance of investigating whether the administration of 
mesenchymal stem cell (MSC)-derived exosomes in clinical settings might set the path for a 
novel and innovative therapeutic concept in stroke. Using an experimental animal model of 
subcortical hemorrhage, the present study investigates for the first time the therapeutic effects 
of the intravenous administration of exosomes, such as inducing functional recovery and 
promoting oligodendrogenesis and white matter fiber repair when axonal tract integrity has 
been compromised. 
 
Materials and methods 
Ethics statement 
In this study, animal care and experimental procedures were strictly in accordance with the 
Guide for the Care and Use of Laboratory Animals, and the study was approved by the 
medical school of La Paz University Hospital’s Ethics Committee for the Care and Use of 
Animals in Research, according to the Spanish and European Union (EU) rules (86/609/CEE 
and RD53/ 2013). This committee includes endpoint criteria. All the animals received a 
postsurgery injection of Meloxicam as analgesia, and we have a protocol including the daily 
supervision of animals. If any animals show pain symptoms, they again receive Meloxicam 
as analgesia. Experiments were reported according to all stroke therapy academic industry 
roundtable12,13 and ARRIVE14 guidelines in terms of randomization, blinding and statistical 
powering. 
 
Animals and surgery 
Adult male rats were subjected to an experimental model of intracerebral hemorrhage (ICH). 
Anesthesia was induced using an anesthetic chamber with 8% isoflurane in a 5-L/min oxygen 
flow and the animals were maintained using a face mask with 4% isoflurane in a 2-L/min 
oxygen flow. After intraperitoneal injection of meloxicam (2mg/kg), the animals were placed 
in a stereotactic frame. Craniotomy was performed adjacent to the bregma, and intrastriatal 
white matter injury was induced by injection of 1mL saline containing 0.5 U collagenase type 
IV (Sigma-Aldrich). Stereotaxic coordinates of the injection site with respect to the bregma 
were as follows: 0.04mm posterior, 0.35mm lateral, 0.6mm ventral, as previously described.15 
A total of 54 male Sprague-Dawley rats (8–9 weeks old, weighing 200–250g) were used in 
this study. The study groups were as follows: (I) sham-operation group (n¼10); (II) ICH 
control: ICHþ1ml i.v. saline (n¼20); (III) ICH treated: ICHþ100mg i.v. exosomes (n¼20) 
(Figure 1). An additional four animals were used for biodistribution analysis, which were 
euthanized at 24h after treatment. 
Treatment was administered via the tail vein at 24h after surgery. Within the groups, the rats 
were then randomly divided into two subgroups that were euthanized at 7 days or at 28 days 
(n¼10 each). The allocation of each animal to an experimental group was performed on the 
basis of a simple random choice: throwing a die (less than/equal to three: control; more than 
three: treatment). One rat from the control group and one rat from the treated group were 
excluded from the study because they died during the magnetic resonance procedure. 
 
Cell culture protocol, isolation and exosome characterization 
MSCs obtained from allogeneic adipose tissue of Sprague-Dawley rats (250–300g) were 
cultured. The adipose tissue was digested with collagenase (Sigma-Aldrich) and incubated at 
37C in 5% CO2. On the third pass, the cell cultures were divided into two groups: 
1. 1105 MSCs for characterization. The MSCs were trypsinized and incubated for 20min 
at 4C. The flow cytometry analysis of the CD90þ/CD29þ/ CD45-/CD11b- cells was 
performed using an FACSCalibur flow cytometer and CellQuest Pro software (Becton 
Dickinson). 
2. MSCs for exosome isolation. MSCs were culturedovernight with a free exosome-FBS 
culture medium. After 24h, the cell supernatants were collected and the exosomes 
were extracted using an exosome extraction kit (miRCURYTM Exosome Isolation Kit, 
Exiqon) following the manufacturer’s instructions. Exosomes were used for treatment, 
for biodistribution study and for proteomic analysis. 
 
Finally, the exosomes were characterized by studying morphology and size (<100nm) using 
Nanosight and an electron microscope, and their phenotype expressing Alix and CD63 
markers was examined by using immunofluorescence and Western blot techniques.16 
 
Biodistribution of exosomes 
For the evaluation of exosome biodistribution after treatment, four animals were used. The 
exosomes were labeled with DiI (Celltracker CM-DiI, Invitrogen) prior to administration. 
Cryosections (40mm thick) of the lung, liver, spleen and brain were counterstained with 40, 
6-diamidino-2-phenylindole (DAPI) and biodistribution was analyzed by 
immunofluorescence staining at 24h. 
To characterize which cell type contained the administered exosome in the brain, we did a co-
staining with DiI-labeled exosomes and VEGF (1:500, Millipore), NeuN (1:100, Millipore), 
CNP-ase (1:500, SigmaAldrich) and Iba-1 (1:1000, Millipore), followed by the goat anti-
mouse and anti-rabbit Alexa Fluor 488 antibody (1:750, Invitrogen). Images were acquired as 
a confocal maximum projection using a Leica TCS-SPE confocal microscope and the number 
of double-positive cells was counted in a minimum of 10 different microscopic fields using a 
40 objective lens and ImageProPlus 4.1 software. 
 
Functional evaluation scales 
Functional evaluations were performed for all the animals by a blinded observer before 
surgery and after 48h, 7 days and 28 days. Motor performance was evaluated using the beam 
walking, Rogers and Rotarod tests. The Beam Walking test measured the ability of the rats to 
walk along a wooden beam (2.52.580cm). Scores were assigned as follows: 0, traversed the 
beam with no foot slip; 1, traversed with grasping of the lateral side of the beam; 2, difficulty 
crawling along the beam but able to traverse; 3, required >10 s to traverse the beam because 
of difficulty with walking; 4, unable to traverse the beam; 5, unable to move the body or any 
limb on the beam; and 6, unable to stay on the beam for >10s.17 The Rotarod test measured 
the time to fall from a rotating cylinder.5 A variant of Rogers’ functional scale was used to 
assign scores as follows: 0, no functional deficit; 1, failure to extend forepaw fully; 2, 
decreased grip of forelimb while tail gently pulled; 3, spontaneous movement in all directions, 
contralateral circling only if pulled by the tail; 4, circling; 5, walking only when stimulated; 
6, unresponsive to stimulation with a depressed level of consciousness; and 7, dead.18 Animals 
had ever reached more than a score of 4 in the Rogers test. The researchers recording the data 
were entirely blinded to the experimental groups. 
 
In vivo magnetic resonance imaging 
Lesion size was analyzed after 7 and 28 days by magnetic resonance imaging (MRI) using a 
7-Tesla horizontal bore magnet (Bruker Pharmascan, Ettlingen, Germany) and a T2-weight 
spin eco image. The lesion area was expressed as a percentage of the contralateral hemisphere, 
after correcting for brain edema. For the tractography analysis, diffusion tensor imaging (DTI) 
data were acquired with a spin echo single shot echo planar imaging (EPI) pulse sequence 
using the following parameters: TR/TE 8000/35ms; a signal average of 12, a 30 noncollinear 
diffusion gradient scheme with a diffusion weighting b¼500s/mm2 and b¼1000s/mm2; 18 
slices with a slice thickness of 1.5mm without a gap; and a 3535mm field of view. Total 
imaging time was 1h 44min. All the EPI data were acquired with a single shot EPI sequence, 
9696 matrix, and zero filled-ink space to construct a 128128 image matrix. Fractional 
anisotropy, mean diffusivity, trace, and the eigenvalues and eigenvector maps were calculated 
with a homemade software application written in Matlab (R2007a). The 3D fiber tract map 
was created using MedINRIA DTI Track software (http://www-sop.inia.fr/asclepios/ 
software/MedINRIA). DTI was performed at 7 and 28 days after treatment. The zoomed 
lesion site threedimensional diffusion tensor images were represented using ParaView 4.1.0 
software as previously described.19 The researchers recording the data were entirely blinded 
to the experimental groups 
 
Mapping of motor cortex connections 
Changes in axonal sprouting after treatment were assessed using an intracortical injection of 
the anterograde neuronal tracer biotinylated dextran amine ([BDA] 10000MW, Life 
Technologies, Grand Island, NY, USA). The rats’ motor cortex was injected with BDA at 3 
weeks after treatment in separate cohorts and they were euthanized one week after BDA 
injection (at 28 days after treatment). All the brains were fixed, frozen and coronally sectioned 
at 50mm and were stained with Cy 5-conjugated streptavidin (Jackson ImmunoResearch, 
West Grove, PA, USA). The sections were mounted, cover slipped and visualized under the 
Cy3 filter on a DMLB epifluorescent microscope (Leica Microsystems). The cortical cells 
labeled with BDA were manually quantified using neuroanatomical quantification software 
(StereoInvestigator, MBF Bioscience)20 in four animals, 10 sections in each animal per group. 
Ipsilateral axons of the striatum and cortex were studied. 
We used a retrograde neuronal tracer cholera toxin subunit B (CTB) (Cy3-labeled CTb, List 
Biological Laboratories, Campbell, CA, USA, diluted to 20mg/mL in 10% DMSO) as another 
method to analyze changes in axonal sprouting after treatment. For mapping of CTB axons, 
0.5 uL of CTB (diluted to 20mg/mL in 10% DMSO) was infused with collagenase at the time 
of stroke induction. The animals were euthanized 7d after treatment, and the brains were fixed, 
frozen and coronally sectioned at 50mm. The sections were mounted, cover slipped and 
visualized under the Cy3 filter on a DMLB epifluorescent microscope (Leica Microsystems). 
The cortical cells labeled with CTB were manually quantified using neuroanatomical 
quantification software (StereoInvestigator, MBF Bioscience)20 in four animals, 10 sections 
in each animal per group. Ipsilateral cortical cells were studied. The researchers recording the 
data were entirely blinded to the experimental groups. 
 
Immunofluorescence and western blot analyses 
Frozen sections were stained using the CryoMyelin Kit (Hitobiotech), which allows sensitive 
localization and visualization of myelin fibers. The mean intensity of myelin staining in the 
region of interest (ROI) was quantified using a Nikon Eclipse-Ti inverted microscope and 
NIS-elements software. 
The lesion area was studied in detail using immunofluorescence and Western blot analyses, 
and the various antibodies used for these evaluations were CNPase (1:500, Sigma-Aldrich), 
A2B5 (1:500, Millipore) and MOG (1:100, Abcam), followed by goat anti-mouse and anti-
rabbit Alexa Fluor 488 (1:750, Invitrogen). 
For the Western blot analysis, the units were normalized based on B-actin (1:400, Sigma-
Aldrich). To quantify the expression of white matter-associated markers, the mean 
fluorescence intensity was evaluated using a 40 objective lens. The experiments, images and 
quantification of the samples were performed by blinded observers using the same microscope 
configurations to eliminate bias due to background normalization (4 animals for each group, 
5 sections in each animal per group, 10 different microscope fields). The researchers recording 
the data were entirely blinded to the experimental groups. 
 
Proteomics data analysis 
For the proteomics analysis of exosome content, proteins were digested using the filter-aided 
sample preparation protocol.21 Peptides were loaded into the LC-MS/MS system for online 
desalting onto C18 cartridges and were analyzed by LC-MS/MS using a C-18 reversed phase 
nano-column (75mm I.D.50cm, 2mm particle size, Acclaim PepMap RSLC, 100 C18; 
Thermo Fisher Scientific, Waltham, MA, USA). A flow rate of 200 nL/min was used to elute 
peptides from the RP nano-column to an emitter nanospray needle for real-time ionization 
and peptide fragmentation on an Orbitrap Elite mass spectrometer (Thermo Fisher). An 
enhanced FT-resolution spectrum (resolution¼35,000) followed by the MS/MS spectra from 
the most intense 15 parent ions was analyzed along the chromatographic run. Dynamic 
exclusion was set at 30s. 
For peptide identification, all the spectra were analyzed with Proteome Discoverer (version 
1.4.0.29, Thermo Fisher Scientific) using SEQUEST-HT (Thermo Fisher Scientific). For 
database searching, the false discovery rate was calculated using inverted databases and the 
refined method.22 For the study of the biological functions of identified proteins, a gene 
ontology analysis was performed using the Gene Ontology enRIchment anaLysis and 
visualization (GOrilla) research tool.23 
 
Statistical analysis 
The results were expressed as meanstandard error and the data were compared using the 
Kruskal–Wallis test followed by the Mann–Whitney test. The Beam Walking and Rogers test 
data are categorical; thus, the data have been presented as median and interquartile range. T2 
and Tractography data were expressed as meanstandard deviation. Values of p<.05 were 
considered significant at a 95% confidence interval; the data were calculated using statistical 
SPSS 16 and GraphPad software. The power analysis showed that with nonparametric testing, 
at least 10 animals needed to be randomized to each group for a significance level of 5% 
(alpha) and a potency of 80% (1-beta). 
 
Results 
Exosome characterization and biodistribution 
Regarding exosome characterization, we used four techniques: NanoSight, electron 
microscope, immunofluorescence and Western blot. The exosomes showed typical 
morphology and size (<100nm) using NanoSight (Figure 2(a)) and an electron microscope 
(Figure 2(b)). Their phenotype was CD-63 (specific marker of exosome) as shown by 
immunofluorescence (Figure 2(c)) and Alix for the Western blot technique (Figure 2(d)). 
Regarding biodistribution of the DiI-labeled exosomes, we analyzed histological sections of 
various organs. We found the DiI marker not only in the brain tissue but also in the peripheral 
organs such as the lung, liver and spleen at 24h after administration (Figure 2(e)). We also 
found co-labeling between DiI and VEGF, NeuN, CNP-ase and Iba-1 at 24h after exosome 
administration (Figure 2(f)). 
 
Effect of exosome treatment on functional recovery 
No significant differences were found in the functional outcome of the treated and control 
animals at 24h and 7 days after treatment (p>.05). However, compared with the control group, 
the treated animals showed significantly better beam walking (1.000.94 vs. 1.900.74 points 
of the score, respectively; p¼.03), Modified Rogers’ test (0.390.67 vs. 1.500.85 points of the 
score, respectively; p¼.003) and Rotarod test performances (98.5023.43 vs. 
76.3024.66seconds, respectively; p¼.05) 28 days after exosome treatment (Figure 3(a)). 
 
Effect of exosome treatment on lesion size and tract connectivity 
The lesion size viewed on MRI in the exosome-treated animals was indistinguishable from 
the control group at seven days (14.42%3.65% vs. 14.05%0.45%). At 28 days, we observed 
significant differences between the ICH treated animals (9.08%0.72%) compared with the 
ICH controls (10.60%0.77%) (p¼.028) (Figure 3(b)). 
The DTI tractography data showed similar results in mean axial diffusivity in both the controls 
and the treated groups 7 days after stroke. However, compared with the control animals, those 
rats receiving treatment with exosomes showed significantly improved mean axial diffusivity 
(171.0022.43 vs. 128.6726.08, respectively; p¼.05) at 28 days after treatment (Figure 3(c)). 
 
Axonal sprouting after exosome treatment 
ICH was produced in the subcortical white matter of the striatum. This region contains 
fascicles of axons projecting from the overlying cortex. To map the connections that are 
damaged by stroke, the neuroanatomical tracer CTB was co-injected with collagenase IV. 
Neurons retrogradely labeled with CTB injection into subcortical white matter represent cells 
with damaged axons at the stroke site. CTB-labeled neurons are present in overlying cortical 
areas ipsilateral and contralateral to the stroke site. There was no significant difference in the 
number of CTB-marker neurons between the control and treated groups, which could indicate 
that the severity of white matter injury is similar in both groups (Figure 3(d)). 
Changes in axonal sprouting after treatment using intracortical injection of anterograde 
neuronal tracer with BDA were also analyzed. Motor cortical projections have an important 
role in motor function and movement. The anatomical tracer BDA was injected into the 
forelimb motor cortex 3 weeks after stroke, and the striatal axonal density was studied one 
week after the injection. A statistically significant high number of BDA-labeled axons were 
shown in the striatum in the exosome-treated group compared with the control animals 
(483.9561.21 vs. 109.029.34, respectively; p<.05). These results could indicate that exosome 
treatment produces a significant axonal sprouting response from the ipsilateral cortex to the 
injured striatum. Moreover, we observed an increase in axonal density in the cortex area by 
anterograde BDA tracer in the treated group compared with the control animals (394.6151.08 
vs. 1647.9843.56, respectively; p<.05) at 4 weeks after treatment (Figure 3(e)). 
 
Effect of exosome treatment on oligodendrocyteassociated marker expression 
Considering the expected time-related developmental steps of oligodendrocyte precursor cell 
(OPC) development, the levels of markers related to the first steps of oligodendrocyte 
progenitor cell development were analyzed in the lesion area 7 days after treatment (Figure 
4). 
CNP-ase appears to be one of the earliest indications of oligodendrocyte differentiation. 
Notably, using Western blot analysis, there was a significant increase in CNP-ase marker 
levels in the exosome-treated animals compared with the control animals at 7 days after 
treatment (0.790.11 vs. 0.610.03, respectively; p¼.043) (Figure 4(b) and (d)). 
A2B5 is a cell surface ganglioside epitope expressed in OPC and its levels were higher in the 
exosome-treated animals compared with the control group at 7 days after treatment (1.090.10 
vs. 0.820.13, respectively; p¼.017) (Figure 4(b) and (d)).  
At 28 days after treatment, we analyzed one marker that was related to later developmental 
steps in mature oligodendrocytes (MOGs). After Western blot analysis, there were 
significantly higher levels of MOGs in the animals that received exosomes compared with the 
control group (1.600.22 vs. 1.020.40, respectively, p¼0.05) (Figure 4(a) and (b)). All these 
results were confirmed by immunofluorescence analysis (Figure 4(a) and (d)). 
 
Myelin restoration 
Morphological study using a Hito CryoMyelin staining kit identified the lesion zone in all the 
animals as a subcortical hemorrhage affecting the white matter, with more myelinated axons 
labeled in the exosometreated animals compared with the control group (230.8716.35 vs. 
181.7222.18, respectively, p¼.014) (Figure 4(c) and (d)). 
 
Proteomics analysis of the exosome 
The proteomics analysis of the exosome identified 2416 proteins (Figure 5) that are implicated 
in various cell functions, such as protein binding, macromolecular complex binding, heparin 
binding, protein complex binding, fibronectin binding, endopeptidase regulator activity and 
metal ion binding (Figure 5(a)). All the functions in detail are shown in Figure 5(c). Full 
proteomic data are provided in the supplementary data (S1). Interestingly, some of these 
proteins are involved in brain repair function, including synaptic transmission, neuronal 
differentiation from neural stem cells, angiogenesis, neuronal projections, neurite outgrowth, 
neurite fasciculation and axonal growth. The proteins related to these functions are synaptic 
vesicle membrane protein (VAT1), synaptotagmin-11 (SYT11), protein GDN, mitogen-
activated protein kinase (M3K11), neuronal pentraxin-1 (NPTX1), vascular endothelial 
growth factor (VEGF165R), von Willebrand factor, neuropilin2 (NRP2), neurofascin 
(NFASC), neuronal cell adhesion molecule (NRCAM) and neurofilament (Figure 5(b)). 
 
Discussion 
In the current research for new therapeutic strategies to improve functional and cognitive 
deficits after stroke, axonal sprouting and growth, oligodendrocyte formation, tract 
connectivity and remyelination are necessary for brain repair processes. Thus, the present 
study employed, for the first time, an intravenous infusion of exosomes as a therapeutic 
strategy to repair white matter damage after intracerebral hemorrhage. In this study, after 
biodistribution analysis, the DiI marker was found in the brain and in the peripheral organs 
(liver, lung and spleen). The animals treated with exosomes showed better scores in functional 
tests, increased mean axial diffusivity by DTI-tractography and more axons, oligodendrocyte-
associated marker expression and increased myelin staining. These results could support a 
role for MSC-derived exosomes in improving the repair of white matter in intracerebral 
hemorrhage. 
Proteomics analysis of the exosomes identified 2416 proteins that are implicated in brain 
repair function, including synaptic transmission, neuronal differentiation from neural stem 
cells, angiogenesis, neuronal projections, neurite outgrowth, neurite fasciculation and axonal 
growth. 
The high frequency of white matter damage in hemorrhage motivates the search for an 
effective therapy to enhance the mechanisms underlying the repair of damaged white matter 
(axons and myelin). Stem cell therapy is emerging as a viable repair therapy in stroke.3,4,15 
MSCs used as cell therapy might act as remote bioreactors leading to systemic remote effects 
on the central nervous system.24 Accordingly, the mechanisms by which the stem cells induce 
these functional improvements might be related to intercellular communication that can occur 
not only by direct cell-to-cell contact, but also by paracrine function by extracellular vesicles 
called exosomes through secreting factors in the extracellular environment. Thus, 
extracellular vesicles might partially explain the paracrine effects observed in stem cell-based 
therapeutic approaches and can play a beneficial role in restoring tissue and organ damage. 
Exosomes purified from MSCs have generated greater interest based on their ability to reduce 
apoptosis/ necrosis in rodents after ischemic injury to the heart,25 brain,9 lung,26 liver27 and 
kidney.28 Some studies have shown that the GFP-tagged exosome-enriched extracellular 
particles released from MSCs intravenously administered to rats with stroke were transferred 
to adjacent astrocytes and neurons.11 In the present study, immunofluorescence for DiI-pre-
labeled exosomes showed both intracellular and extracellular staining of DiI in the brain (area 
of injury) and colabeling with VEGF, NeuN, GFAP and Iba-1. DiI labeling was found not 
only in the brain, but also in peripheral organs such as the lung, liver and spleen at 24h after 
treatment. Further investigation is warranted to determine whether these nano-sized exosomes 
are trapped in those organs and have remote effects on the brain. 
Regarding functional recovery, previous studies by our group have demonstrated 
improvement in functional outcome after MSC administration following intracerebral 
hemorrhage.4 However, whether exosomes produced by MSCs had this function, mirroring 
that of their parent cells was still unknown. The present study demonstrated that rats receiving 
exosomes generated by MSCs showed better scores in functional tests in intracerebral 
hemorrhage 28 days after treatment. This result agrees with some studies that demonstrated 
systemic administration of MSC-generated exosomes significantly improved functional 
recovery in other experimental animal models of stroke (ischemia)7,9,29 and traumatic brain 
injury.30 
The mechanisms by which exosomes act are still unknown; further investigation is required. 
Recent studies demonstrate that intravenous administration of cellfree MSC-generated 
exosomes enhances neurovascular plasticity and neurite remodeling in rats after stroke.9 In 
our study, neurons were anterogradely labeled by a BDA injection into the cortex three weeks 
after stroke to map the connections that were growing after treatment. A statistically 
significant high number of BDA-labeled axons were shown in the striatum of the treated group 
compared with the control animals. These results might indicate that exosome treatment 
produces a significant axonal sprouting response from the ipsilateral cortex to the injured 
striatum. All these results agree with those obtained analyzing fiber tract integrity by DTI 
tractography. The animals receiving exosomes showed higher mean axial diffusivity 
compared with controls. These results could indicate that tract thickness was recovered at 28 
days after exosome administration. These results suggest that good functional recovery at 28 
days could be related to axonal sprouting white matter thickness (width, breadth, depth) and 
restoration of tract connectivity in the exosome-treated animals. For this reason, exosome 
administration could be involved in the process by which restructured axons, which had 
previously been compromised and demyelinated, recover not only their proper structure but 
also tract connectivity. These results are consistent with previous data showing neurite 
remodeling in the cortical ischemic boundary zone after other types of stroke.9 
After a subcortical stroke, not only axonal and tract restoration but also oligodendrocyte and 
myelin formation are involved in a correct brain repair process. In this type of subcortical 
stroke, myelin injury activates the OPCs distributed throughout the white matter, which 
proliferate and migrate to the site of damage where they subsequently mature into myelinating 
oligodendrocytes that ensheath axons to form the myelin membrane.31 To elucidate whether 
exosome administration also acts on oligodendrocytes and shattered white matter fibers, we 
measured oligodendrocyte-associated markers in both the treated and the control animals. 
Related to the first steps of the genesis and migration of OPCs, markers such as A2B5 (a 
characteristic OPC marker) and CNP-ase (a marker related to immature oligodendrocytes) 
were studied in the lesion area at 7d after treatment. Markers related to white matter 
differentiation and myelin fiber maturation such as MOGs were analyzed at 28 days. 
The best-characterized oligodendroglial progenitor marker is A2B5.32 This molecule is a cell 
surface ganglioside expressed on developing oligodendroglial progenitors. In our study, the 
levels of the A2B5 marker were higher in the cell-free exosomes generated by the MSC-
treated animals at 7 days than in the control group. This observation agrees with a study 
describing the levels of CNP-ase. The presence of CNP-ase appears to be one of the earliest 
events in oligodendrocyte differentiation.33 The exosome-treated animals showed higher 
levels of CNP-ase than the control group. Regarding the oligodendrocyte 
maturationassociated proteins, the levels of MOG markers were found to be elevated in the 
exosome-treated animals compared with the control animals at 28 days. 
Not only are axons important in the process of white matter repair, but also the myelin sheath, 
which allows the transmission of nerve impulses over relatively long distances; a process 
necessary for whole brain function. A cryomyelin study showed an increase in myelination in 
those animals that received treatment with exosomes compared with the control group. What 
is unknown is whether the increased myelination was because more axons were being 
myelinated or whether there was an overall increase in myelin thickness. 
Based on the results obtained in this study, we can conclude that exosomes enhance the natural 
repair processes of the brain after injury. However, the mechanisms underlying these repair 
processes are still unknown, given the identity of which components of the exosomes’ 
proteome are responsible for this effect remains elusive. Our proteomics analysis identified 
2416 proteins; some of these proteins are associated with several brain functions, such as 
synaptic transmission (VAT1, SYT11, NPTX1), neuronal differentiation from neural stem 
cells (GDN, NPTX1), apoptosis (M3K11, NPTX1), angiogenesis (VEGF165R, von 
Willebrand factor), neuronal projections (NRP2), neurite outgrowth, neurite fasciculation and 
axonal growth (NFASC, NRCAM, NF). All these functions are associated with brain repair 
after stroke. These results agree with other studies that revealed exosomes from MSCs 
reduced inflammation and increased cell proliferation during tissue repair following other 
types of stroke in rats, promoting angiogenesis, neurogenesis, neurite outgrowth and 
recovery.9,34 
The gene ontology analysis revealed that protein binding, macromolecular complex binding, 
heparin binding, protein complex binding, fibronectin binding, endopeptidase regulator 
activity and metal ion binding were the most important functions of the identified proteins. 
Interestingly, growth factor activity was not the primary represented function in the cell 
secretome, indicating that other functions are also relevant. Our findings suggest that the 
identified proteins could contribute to improved functional recovery after exosome 
administration. When the specific molecules necessary for a therapeutic effect are known, 
selective manipulation of the expression of those molecules might lead to an enhancement of 
the therapeutic efficiency of isolated exosomes. 
Finally, the therapeutic use of exosomes can be advantageous because of their ability to reduce 
the high production costs of stem cell treatment. For therapeutic treatment, exosomes can be 
frozen and stored in hospital freezers, as needed. For example, this treatment can be 
immediately administered to the patient upon admission and diagnosis; thus, treatment can be 
administered in the acute phase of stroke. Moreover, using exosomes as alternative therapy 
for stroke would decrease the cost of treatment. 
In conclusion, in the current research, we have demonstrated for the first time that rats 
receiving exosomes derived from adipose-derived MSCs as a therapeutic strategy showed 
improved functional recovery after intracerebral hemorrhage, more axons, a higher expression 
of oligodendrocyte formation markers, higher tract connectivity and greater myelin staining, 
which are necessary for brain repair processes. Proteomic analyses identified 2416 proteins, 
some of these are associated with several brain functions. Thus, exosome treatment could be 
a heterogeneous process by nature, with many factors that can influence brain plasticity in an 
adaptable and versatile way; however, future work will be necessary to confirm their 
implications in intracerebral hemorrhage. 
 
Limitation of the study 
A limitation of the present study is that only males were used for the experiments. Following 
the STAIR recommendations, future studies should be performed in both males and females 
in order to translate preclinical studies to the clinic. 
Another limitation of this study is regarding ICH induced by collagenase IV; the levels of this 
enzyme are significantly greater than the levels of endogenous collagenase in clinical ICH, 
which might not allow this model to faithfully emulate the pathological alterations involved 
in ICH in the clinical setting. The disadvantages of this model are related to bacterial 
collagenase’s ability to introduce an inflammatory reaction. Moreover, in opposition to ICH 
in patients in which the solid hematoma is a result of bleeding from the arterial source in brain 
tissue, bleeding in the collagenase model is diffuse and results from rupture of small blood 
vessels around the site of collagenase injection.35 However, any experimental animal model 
reproduces completely the clinical disease. Most of the studies based on experimental animal 
models of hemorrhage use collagenase Type IV in order to induce ICH. 
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Figure 1. Experimental protocol schematic. (a) Rats were subjected to an ICH by collagenase IV 
injection. Twenty-four hours later, rats received treatment (saline or exosomes). At 48 h, histological 
studies for biodistribution of exosomes were performed. (b) Rats were injected with collagenase IV 
to induce hemorrhagic stroke. During the same surgery, animals were inoculated with CTB as 
retrograde tracer. At 24 h poststroke, treatment (saline or exosomes) was administered through the 
tail vein. Later, 48 h after ICH and on day 7, behavior and imaging studies were evaluated. Seven days 
after ICH, histological studies were analyzed. (c) Rats were subjected to an ICH by collagenase IV and 
received treatment 24 h later (saline or exosomes). Forty-eight hours after ICH, on days 7 and 28, 
behavior and imaging studies were evaluated. BDA was injected as anterograde tracers 21 days after 
ICH. Histological studies  were analyzed 28 days after ICH. 
 
Figure 2. Exosome characterization and biodistribution. Exosomes were characterized using various 
techniques: (a) NanoSight, (b) electron microscope, (c) immunofluorescence and (d) Western blot. (e) 
DiI-exosomes were observed by immunofluorescence (red) after i.v. administration into the lung, liver, 
spleen and brain. (f) DiI co-localization was shown with VEGF, NeuN, CNP-ase and Iba-1 in brain samples. 
(Data are shown as mean  SEM, *p<.05; n ¼ 4 animals per group).  
 
   
Figure 3. Improved functional outcome reduced infarct size and increased fiber tract and axonal 
sprouting after exosome treatment in intracerebral hemorrhage. (a) Beam Walking test performance 
(left) (data are shown as medianinterquartile range, *p<.05; n¼10 animals per group), the Rogers test 
(middle) (data are shown as medianinterquartile range, *p<.05; n¼10 animals per group), and the 
Rotarod (right) (data are shown as bar graph, n¼10 animals per group) was improved at 28 days (p<.05) 
in the treatment group compared with the controls (p<.05). (b) Comparative image analysis of T2-
weighted MRI at 7 and 28 days showed a progressive reduction in white matter infarct size of 
hemorrhagic stroke in the treated animals. (Data are shown as meanSD, *p<.05, n¼4 animals) (c) 
Comparative image analysis of tractography showed significant high tract connectivity in the treated 
animals compared with the controls at 28 days after treatment. Detail of tractography image in the 
lesion is displayed below, showing augmented connectivity of  fiber tracts at 28 days. Quantitative 
analysis of MRI images and tractography. (Data are shown as meanSD, *p<.05, n¼4 animals). (d) 
Representative photomicrographs and quantification of cortical neuronal projections through the 
stroke site, labeled with the anatomical tracer cholera toxin subunit B (CTB). (e) Photomicrographs of 
cortical cells previously labeled with BDA and striatal axons from cortical cells labeled with biotinylated 
dextran amine (BDA) (left). Quantification of cortical BDA axons and striatal BDA axons (right). (Data are 
shown as meanSEM, *p<.05, n¼4 animals, 10 sections in each animal per group). 
  
 
Figure 4. White matter-associated markers are enhanced after exosome therapy in subcortical stroke 
model. (a) Immunofluorescence images of white matter repair-associated markers (CNP-ase, A2B5 and 
MOG). (b) Western blot images. (c) Morphological study by CryoMyelin staining identified the zone of 
the lesion as an area of white matter injury located in the subcortical zone, showing restored myelinated 
axons in the exosome-treated animals. (d) Western blot and IF quantification of white matter repair-
associated markers and quantification of mean ROI intensity of the CryoMyelin staining, respectively. 
Stroked line indicates ROI; yellow line indicates a representative longitudinal profile of pixel intensity. 
(Data are shown as meanSEM, scale bars¼20 mm, *p<.05, n¼4 animals, 5 sections in each animal per 




Figure 5. Proteomics analysis of the adipose-derived MSC secretome reveals multiple biological 
functions. (a) Gene ontology (GO) analysis of the 2416 proteins identified by the Orbitrab proteomic 
study. Bars indicate the number of proteins associated with each biological function. (b) Protein-related 
brain repair process. (c) GO functional clustering of proteins associated with binding function. 
 
